Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ: ANGO )

10.34 -0.19 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 Next >
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.